{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypertension-not-diabetic/prescribing-information/alpha-blockers/","result":{"pageContext":{"chapter":{"id":"5740c79c-d5a7-5547-ab38-db87df2b9121","slug":"alpha-blockers","fullItemName":"Alpha-blockers","depth":2,"htmlHeader":"<!-- begin field 17d2a850-1e1b-486b-a524-a71600db71b5 --><h2>Alpha-blockers</h2><!-- end field 17d2a850-1e1b-486b-a524-a71600db71b5 -->","summary":"","htmlStringContent":"<!-- begin item 05d0c96c-3d19-4e22-9d55-a71600db7224 --><!-- end item 05d0c96c-3d19-4e22-9d55-a71600db7224 -->","topic":{"id":"c1c1e500-a3f1-5baa-8d5f-890b15f767cc","topicId":"8de59d12-a526-4ab9-8496-1fcb59d838ff","topicName":"Hypertension - not diabetic","slug":"hypertension-not-diabetic","lastRevised":"Last revised in September 2020","chapters":[{"id":"2f82c42a-b82b-549e-9b10-218d9f782bf8","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a5985652-a8b7-51c0-b2d2-6836d4507f90","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"95f1a40b-c079-5c37-af45-5e0806a2bcae","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4f16b189-bff9-5dfe-82a9-fdd4cd035ab0","slug":"changes","fullItemName":"Changes"},{"id":"a4dad1ea-40da-5ed2-85b0-8b5ea72bc196","slug":"update","fullItemName":"Update"}]},{"id":"b0107535-58ec-5e22-ac3b-22ae41ade390","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f76e08e3-badc-526a-835f-8f549cc3f784","slug":"goals","fullItemName":"Goals"},{"id":"928c1147-d56a-5b8a-94f7-87ddad3ef460","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"aae28613-e6a5-5ba1-b4fa-e5032a9918ac","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7bf8c570-8757-5ae3-802f-5cba9e5ceb86","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3ace22a3-d042-5a6a-9d63-3527cf484a0a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c1a38cc6-4765-5c16-9f08-592cfc9851a3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"066993d8-fd33-59fb-877b-6e8418b515d1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"15ade196-5491-5552-9df6-a17d4c9c69d7","slug":"definition","fullItemName":"Definition"},{"id":"4528059a-b33b-51d3-8c65-983b4c165a3a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"3e698434-11c9-553c-96a6-a249bf121cbb","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"0bec257d-f02e-5030-a430-8accc5245e7f","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"e56e7d7e-9afc-5c38-a77a-8f2b80461457","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7dcedb3e-c4f4-55ff-9910-03ee5ed41bb4","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"a6466983-7adb-5a4f-8864-f3ecc06b447a","slug":"investigations","fullItemName":"Investigations"}]},{"id":"33227758-4699-5e51-be33-b22dca2eb654","fullItemName":"Management","slug":"management","subChapters":[{"id":"d6332f04-a86e-56ef-9e25-d77083a8371c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"0cfca07e-cadc-55c1-81ed-fcdb236f4835","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"92190a49-9e8d-5fae-93b2-cf6243cfc01b","slug":"angiotensin-converting-enzyme-inhibitors","fullItemName":"Angiotensin-converting enzyme inhibitors"},{"id":"5ee249d0-bc66-59a5-8138-2449798ff2eb","slug":"angiotensin-ii-receptor-blockers","fullItemName":"Angiotensin-II receptor blockers"},{"id":"115bec24-ba4e-5f2a-80dc-dee6e948a288","slug":"thiazide-type-diuretics","fullItemName":"Thiazide-type diuretics"},{"id":"2ae4ccdd-d119-5a5a-9c89-d6493f2552f2","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers"},{"id":"44681f3b-7958-5edd-a944-eb440f1df250","slug":"spironolactone","fullItemName":"Spironolactone"},{"id":"cb9a67f7-3588-5c68-b3d5-6c63d50ad0b8","slug":"beta-blockers","fullItemName":"Beta-blockers"},{"id":"5740c79c-d5a7-5547-ab38-db87df2b9121","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"f3424e7c-5446-59b0-b50e-0724587bb306","slug":"covid-19","fullItemName":"COVID-19"}]},{"id":"3b3191c9-bff5-563f-b5c0-09e8a0d22441","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7d204db0-8ff2-556e-97b4-89516ac7819b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0f686cda-dcaf-5f12-b5d6-871aefae47fe","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"dfcaec55-3c23-5a3f-9c08-f151a3120dc2","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"804073cd-b49f-5e4a-bf85-90faf125ad0e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"613e4289-93db-5311-aa87-b5a7a6e82dd1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e42a873-c39f-5405-bf4f-efdd81187ea2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2b87bc1c-2b4a-556b-b320-6b4f18bcf85d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0cfca07e-cadc-55c1-81ed-fcdb236f4835","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"2e11549f-a8b2-57f7-87b7-0db42fa520fa","slug":"choice-of-alpha-blocker","fullItemName":"Choice of alpha-blocker","depth":3,"htmlHeader":"<!-- begin field 30a8d75d-a066-42bd-a013-a71a00ca14ea --><h3>Which alpha-blocker is recommended?</h3><!-- end field 30a8d75d-a066-42bd-a013-a71a00ca14ea -->","summary":"","htmlStringContent":"<!-- begin item 9bac6ac1-b1f6-4b21-bfdb-a71a00ca14d6 --><!-- begin field d5412ec0-8ac8-439f-bf0d-a71a00ca14ea --><ul><li>Once-daily doxazosin and terazosin are recommended alpha-blocker drug options.</li><li>Prescribe non-proprietary drugs where these are appropriate and minimise cost.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>] </p><!-- end field d5412ec0-8ac8-439f-bf0d-a71a00ca14ea --><!-- end item 9bac6ac1-b1f6-4b21-bfdb-a71a00ca14d6 -->","subChapters":[]},{"id":"2d78c701-a27b-5c58-961e-7d972fe5346a","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 542c6ccd-791e-4c7d-94d4-a71a00ca3186 --><h3>Contraindications and cautions</h3><!-- end field 542c6ccd-791e-4c7d-94d4-a71a00ca3186 -->","summary":"","htmlStringContent":"<!-- begin item 324ee7c4-eb01-48d3-984f-a71a00ca30ec --><!-- begin field d9523939-2416-402f-8b32-a71a00ca3186 --><ul><li><strong>Do not use alpha-blockers</strong> if there is a history of:<ul><li>Postural hypotension</li><li>Micturition syncope (in people with benign prostatic hypertrophy).</li></ul></li><li><strong>Do not use modified-release doxazosin tablets</strong> in people with gastrointestinal obstruction, oesophageal obstruction, or any degree of stricture, as the outer membrane of the formulation is not digested.</li><li><strong>Prescribe alpha-blockers with caution to people with Raynaud's phenomenon.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017m</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017n</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field d9523939-2416-402f-8b32-a71a00ca3186 --><!-- end item 324ee7c4-eb01-48d3-984f-a71a00ca30ec -->","subChapters":[]},{"id":"6257f37f-4ba8-550e-9445-5f91c957ce84","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 2803ea4b-5c94-4746-a18b-a71a00ca6806 --><h3>Adverse effects</h3><!-- end field 2803ea4b-5c94-4746-a18b-a71a00ca6806 -->","summary":"","htmlStringContent":"<!-- begin item 8488536c-23b7-4b9b-abd5-a71a00ca6832 --><!-- begin field c0f6516d-3479-49d8-b9d6-a71a00ca6806 --><ul><li><strong>Adverse effects of doxazosin include:</strong><ul><li>Anxiety.</li><li>Back pain.</li><li>Coughing.</li><li>Dyspnoea.</li><li>Fatigue.</li><li>Influenza-like symptoms.</li><li>Myalgia.</li><li>Paraesthesia.</li><li>Sleep disturbance.</li><li>Vertigo.</li></ul></li><li><strong>Adverse effects of prazosin include:</strong><ul><li>Blurred vision.</li><li>Depression.</li><li>Dizziness.</li><li>Drowsiness.</li><li>Dry mouth.</li><li>Dyspnoea. </li><li>Gastro-intestinal disturbances.</li><li>Headache.</li><li>Nasal congestion.</li><li>Nervousness.</li><li>Oedema.</li><li>Palpitations.</li><li>Syncope.</li><li>Urinary frequency.</li><li>Vertigo.</li><li>Weakness.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017m</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017n</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field c0f6516d-3479-49d8-b9d6-a71a00ca6806 --><!-- end item 8488536c-23b7-4b9b-abd5-a71a00ca6832 -->","subChapters":[]},{"id":"b27ea8bd-18bf-5cf1-be40-7cd58fea1aca","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 4613e76d-7f17-49ef-8cc3-a71a00caa46c --><h3>Drug interactions</h3><!-- end field 4613e76d-7f17-49ef-8cc3-a71a00caa46c -->","summary":"","htmlStringContent":"<!-- begin item 044c1df5-62c4-447f-a694-a71a00caa618 --><!-- begin field f3cd889c-ba6f-4867-8363-a71a00caa46c --><p><strong>Drug interactions with alpha-blockers include:</strong></p><ul><li><strong>Alprostadil, ACE-inhibitors, angiotensin-II receptor blockers, antipsychotics, anxiolytics, baclofen, beta-blockers, calcium channel blockers, clonidine, co-beneldopa, co-careldopa, diazoxide, diuretics. hydralazine, hypnotics, levodopa, MAOIs, methyldopa, minoxidil, moxonidine, nitrates, sodium nitroprusside, tizanidine </strong>— enhanced hypotensive effect.</li><li><strong>Corticosteroids, oestrogens</strong> — hypotensive effect antagonised with concomitant use.</li><li><strong>Cytochrome P450 3A4 (CYP 34A) inhibitors</strong> — the manufacturer advises that caution should be exercised if doxazosin is administered with CYP 34A inhibitors, such as clarithromycin, itraconazole, ritonavir, and voriconazole [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2019</a>].</li><li><strong>Midodrine</strong> — alpha-blockers possibly antagonise effects of midodrine.</li><li><strong>Moxisylyte </strong>— increased risk of severe postural hypotension.</li><li><strong>Non-steroidal anti-inflammatory drugs</strong> — hypotensive effect antagonised with concomitant use.</li><li><strong>Phosphodiesterase-5 inhibitors (for example avanafil, sildenafil, tadalafil, vardenafil)</strong><ul><li>Combined use with alpha-blockers may lead to symptomatic hypotension in some people. To minimize the risk of postural hypotension, the person should be stable on the alpha-blocker before initiating phosphodiesterase-5 inhibitors.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017m</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017n</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field f3cd889c-ba6f-4867-8363-a71a00caa46c --><!-- end item 044c1df5-62c4-447f-a694-a71a00caa618 -->","subChapters":[]},{"id":"3789757b-b67e-5c6a-870b-0ffb6e2b8f10","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field 9c16a79f-7306-43b6-8d56-a71a00ca471f --><h3>Dose and titration</h3><!-- end field 9c16a79f-7306-43b6-8d56-a71a00ca471f -->","summary":"","htmlStringContent":"<!-- begin item 0f486329-7b1e-494e-87ef-a71a00ca4884 --><!-- begin field a2146c0e-d9ff-4aa6-b4cb-a71a00ca471f --><ul><li><strong>Doxazosin (non-modified release)</strong><ul><li>Standard initiation dosage is 1 mg per day.</li><li>Titrate upwards by doubling the dose every 4 weeks.</li><li>Usual maintenance dosage is 4 mg per day.</li><li>Maximum dosage is 16 mg per day.</li></ul></li><li><strong>Doxazosin (modified release)</strong><ul><li>Standard initiation dosage is 4 mg per day (optimal effect can take up to 4 weeks).</li><li>Usual maintenance dosage is 4 mg per day.</li><li>Maximum dosage is 8 mg per day.</li></ul></li><li><strong>Prazosin (non-modified release)</strong><ul><li>Standard initiation dose is 500 micrograms, to be taken in the evening.</li><li>Increase to 1 mg </li><li>Titrate the dose upwards every 4 weeks.</li><li>Usually maintain at a dosage of 2–10 mg per day (divided doses may be required).</li></ul></li><li>For non-modified-release alpha-blockers — advise the person to take the first dose in the evening:<ul><li>If symptoms of hypotension occur, advise them to go to bed and take no further doses until they have been reviewed.</li><li>If the drug is well tolerated, subsequent doses can be taken in the morning.</li></ul></li><li>Reassess response to treatment after at least 4 weeks, unless it is necessary to reduce the blood pressure more urgently.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017m</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017n</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field a2146c0e-d9ff-4aa6-b4cb-a71a00ca471f --><!-- end item 0f486329-7b1e-494e-87ef-a71a00ca4884 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}